注射用胰激肽原酶治疗糖尿病肾病临床探究.doc

注射用胰激肽原酶治疗糖尿病肾病临床探究[摘要] 目的 分析注射用胰激肽原酶治疗糖尿病肾病（Diabetic nephropathy，DN）的疗效和安全性。方法 60例DN患者分为观察组和对照组两组。对照组给予卡托普利治疗；观察组在对照组的基础上，加用注射用胰激肽原酶治疗。结果 治疗后，观察组24h尿蛋白定量、UAER下降明显多于对照组，差异有显著性（P＜0.01）。治疗后，观察组血液流变学各项指标下降明显多于对照组，差异有显著性（P＜0.01）。两组均未见明显的不良反应。结论 注射用胰激肽原酶治疗DN患者疗效佳，安全性高。 [关键词] 注射用胰激肽原酶；卡托普利；糖尿病肾病 [中图分类号] R587.2 [文献标识码] B [文章编号] 1673-9701（2011）26-64-02 Clinical Research of Pancreatic Kininogenase for Injection Joint Captopril Treatment of Diabetic Nephropathy XU Hong Pharmacy Department of Wuyuan People’s Hospital in Jiangxi Province，Wuyuan 333200，China [Abstract] Objective To observe the efficacy and safety evaluation of Pancreatic Kininogenase for injection joint captopril treatment of DN. Methods All 60 patients with DN were divided into observation group and control group. Control group：captopril treatment. Observation group：captopril treatment joint Pancreatic Kininogenase for injection. Results After treatment，the 24h urine protein quantitative and UAER down of the observation group were higher than those in the control group，the differences were significant（P＜0.01）. After treatment，the index of blood rheology decline of the observation group were higher than those in the control group，the differences were significant（P＜0.01）. Two groups did not observed the obvious adverse reactions. Conclusion Pancreatic Kininogenase for Injection treatment of DN curative effect is good，the side effect is small. [Key words] Pancreatic Kininogenase for injection；Captopril；Diabetic nephropathy 糖尿病肾病（Diabetic nephropathy，DN）是糖尿病患者主要的微血管并发症[1]，也是其致死、致残的重要原因之一[2]，而且临床常见多发，其发生率也随着糖尿病病程的延长而不断增高。本课题中，笔者采用注射用胰激肽原酶治疗糖尿病肾病患者，结果疗效满意，现报道如下。 1 资料与方法 1.1 一般资料 选择2009年1月～2011年6月在婺源县人民医院就诊的DN患者60例（男33例/女27例），年龄38～77岁，病程2～10年，按就诊顺序分为观察组和对照组。观察组30例（男15例/女15例），平均年龄（54.7±6.4）岁，平均病程（5.3±2.4）年；对照组30例（男18例/女12例），平均年龄（54.5±6.3）岁，平均病程（5.5±1.9）年。两组DN患者年龄、病程等一般资料差异无统计学意义（P＞0.05），具有可比性。 1.2 方法 ①对照组：在常规饮食控制加口服降糖药的基础上，给予卡托普利片（中美上海施贵宝制药，国药准字，12.5～25mg，3次/d。②观察组：在对照组的